Principal Financial Group Inc. Purchases 2,793,333 Shares of Haleon PLC Sponsored ADR $HLN

Principal Financial Group Inc. grew its holdings in shares of Haleon PLC Sponsored ADR (NYSE:HLN) by 27,393.7% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,803,530 shares of the company’s stock after acquiring an additional 2,793,333 shares during the period. Principal Financial Group Inc.’s holdings in Haleon were worth $28,063,000 as of its most recent SEC filing.

Several other hedge funds have also recently made changes to their positions in HLN. Brighton Jones LLC acquired a new position in shares of Haleon in the 4th quarter valued at about $187,000. AQR Capital Management LLC grew its stake in Haleon by 22.5% during the first quarter. AQR Capital Management LLC now owns 96,323 shares of the company’s stock worth $991,000 after purchasing an additional 17,720 shares during the period. Focus Partners Wealth grew its stake in Haleon by 7.6% during the first quarter. Focus Partners Wealth now owns 73,106 shares of the company’s stock worth $752,000 after purchasing an additional 5,178 shares during the period. Geneos Wealth Management Inc. increased its holdings in Haleon by 33.0% in the first quarter. Geneos Wealth Management Inc. now owns 4,846 shares of the company’s stock worth $50,000 after purchasing an additional 1,203 shares in the last quarter. Finally, CW Advisors LLC increased its holdings in Haleon by 11.6% in the second quarter. CW Advisors LLC now owns 25,075 shares of the company’s stock worth $260,000 after purchasing an additional 2,601 shares in the last quarter. 6.67% of the stock is owned by institutional investors.

Haleon Price Performance

Shares of NYSE HLN opened at $10.10 on Monday. Haleon PLC Sponsored ADR has a twelve month low of $8.65 and a twelve month high of $11.28. The stock’s 50 day moving average price is $9.27 and its 200-day moving average price is $9.86. The company has a market capitalization of $44.46 billion, a PE ratio of 25.88, a PEG ratio of 2.33 and a beta of 0.13. The company has a quick ratio of 0.71, a current ratio of 0.92 and a debt-to-equity ratio of 0.47.

Analyst Ratings Changes

Several equities analysts have issued reports on HLN shares. Wall Street Zen raised Haleon from a “hold” rating to a “buy” rating in a research note on Sunday, July 12th. Rothschild & Co Redburn lowered shares of Haleon from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, June 16th. Weiss Ratings reiterated a “hold (c)” rating on shares of Haleon in a research report on Tuesday, June 30th. Finally, Deutsche Bank Aktiengesellschaft reissued a “sell” rating on shares of Haleon in a research note on Thursday, April 30th. Two research analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy”.

About Haleon

Haleon plc (NYSE:HLN) is a global consumer healthcare company formed through the separation of a large pharmaceutical group’s consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over‑the‑counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self‑care and symptom relief.

The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.